In a clinical study evaluating the efficacy of tremelimumab plus RFA for advanced HCC, it showed that 5 of the 19 evaluable patients achieved partial remission, 12 of 14 HCV+ patients had a significantly reduced viral load, and patients who experienced a clinical benefit had significantly increased CD8+ T-cell numbers, with a median OS of 12.3 months and median time to tumor progression of 7.4 months (24). Here, CD8A is linked to neoplasm.